ClouDr Group Limited

Equities

9955

KYG2216H1011

Medical Equipment, Supplies & Distribution

Market Closed - Hong Kong S.E. Other stock markets 04:08:07 2024-06-03 am EDT			5-day change	1st Jan Change
2.64 ^HKD	-1.12%		-9.59%	-61.46%

Apr. 15	ClouDr Launches Digital Employee to Improve Online-to-Offline Operation Services	MT
Mar. 22	ClouDr Group's Net Loss Shrinks 81% in 2023 as Revenue Rises 23.5%	MT

ClouDr Group Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ending December 31, 2022

December 05, 2022 at 05:05 pm EST

ClouDr Group Limited provided unaudited consolidated earnings guidance for the year ending December 31, 2022. The group expects revenue for the year ending December 31, 2022 to be between approximately RMB 2,700 million to RMB 3,100 million, representing an increase of approximately 53.7% to 76.5% year over year.

Latest news about ClouDr Group Limited

ClouDr Launches Digital Employee to Improve Online-to-Offline Operation Services	Apr. 15	MT
ClouDr Group's Net Loss Shrinks 81% in 2023 as Revenue Rises 23.5%	Mar. 22	MT
ClouDr Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
ClouDr Launches Diabetes Tablets; Shares Up 3%	Mar. 11	MT
ClouDr Group Limited Announces Launch of Proprietary Product, Hetangjin Dapagliflozin Tablets	Mar. 10	CI
ClouDr Group Limited Enters into A Non-Legally Binding Strategic Cooperation Agreement with China Resources Kunming Shenghuo Pharmaceutical Co., Ltd	Mar. 05	CI
ClouDr Buys Back Shares	Jan. 25	MT
ClouDr Group Trustee Buys 1.3 Million Shares Under Award Scheme	Jan. 17	MT
ClouDr Unit to Get 200 Million Yuan Capital Injection	Jan. 12	MT
ClouDr Buys Back Shares for Incentive Scheme	Jan. 11	MT
ClouDr Group Applies to Register Diabetes Digital Therapeutics in China	Jan. 03	MT
ClouDr Group Limited Completes the Application for Registration as A Medical Device in the People's Republic of China in Respect of ClouDT-01	Jan. 03	CI
ClouDr Group to Buy Up to HK$80 Million of Shares	Dec. 28	MT
ClouDr Signs Marketing Deal With Shanxi Jinbo Bio Pharmaceutical	Dec. 28	MT
ClouDr Group Limited Enters into a Non-Legally Binding Strategic Cooperation Agreement with Shanxi Jinbo Bio-Pharmaceutical Co., Ltd	Dec. 27	CI
Cloudr Group Limited Announces Resignation of Liu Mengya as Joint Company Secretary	Dec. 19	CI
ClouDr Group Signs Digital Marketing Agreement with Pharmaceutical Company	Nov. 29	MT
ClouDr Says New Evidence Shows Ischelium Drug's Efficacy on Cognitive Improvement	Nov. 16	MT
ClouDr Group Limited Announces New Efficacy of Ischelium on Brain Covidative Fund Approval	Nov. 15	CI
ClouDr to be Added in MSCI China Small Cap Index	Nov. 15	MT
ClouDr Group Chairman/CEO Boosts Shareholding	23-10-31	MT
ClouDr Group Chairman/CEO Purchases 117,100 Shares; Shares Rise 3%	23-10-30	MT
ClouDr Group Limited(SEHK:9955) added to S&P Global BMI Index	23-09-18	CI
ClouDr Group Chairman and CEO Boosts Shareholding	23-09-11	MT
ClouDr Group to Partner with Hong Kong Magicure to Facilitate Cross-Border Access to Drugs in China	23-09-07	MT

Chart ClouDr Group Limited

Duration

Period

More charts

Company Profile

ClouDr Group Ltd is a China-based holding company principally engaged in the provision of medical services and products. The Company provides medical supplies and software-as-a-service (SaaS) products to hospitals and pharmacies, digital marketing services to pharmaceutical companies, and online consultations and prescriptions to patients. The Company's product portfolio consists of three major product or service categories. The in-hospital solution mainly includes hospital supplies sales, hospital SaaS and digital marketing services. The pharmacy solution mainly includes pharmacy supplies sales and pharmacy SaaS. The individual chronic condition management solution and others mainly include chronic condition products, premium membership services, as well as insurance brokerage services, advertisement agent services and others.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-08-15 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for ClouDr Group Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.473 CNY

Average target price

6.328 CNY

Spread / Average Target

+155.91%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
CLOUDR GROUP LIMITED	-61.46%	200M
ABBOTT LABORATORIES	-7.16%	178B
MEDTRONIC PLC	-1.23%	107B
BECTON, DICKINSON AND COMPANY	-4.86%	67.04B
DEXCOM, INC.	-4.28%	47.23B
CENCORA, INC.	+10.32%	44.62B
HOYA CORPORATION	+9.25%	42.5B
METTLER-TOLEDO INTERNATIONAL, INC.	+15.76%	29.99B
TERUMO CORPORATION	+15.97%	25.22B
WEST PHARMACEUTICAL SERVICES, INC.	-5.88%	24.14B

Other Medical Equipment, Supplies & Distribution